drugset / Trial / NCT01302808
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 1
Completed
17 enrolled
University of Texas Southwestern Medical Center
Celgene Corporation · collabGenentech, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of romidepsin when given together with erlotinib hydrochloride and to see how well they work in treating patients with stage III or stage IV non-small cell lung cancer.
Timeline
- Start
- 2009-09
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Romidepsin | Peptide | 8 mg/m2 | Intravenous |
| Subject | Romidepsin | Peptide | 10 mg/m2 | Intravenous |